The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.

Beltran, Himisha; Hruszkewycz, Andrew; Scher, Howard I; Hildesheim, Jeffrey; Isaacs, Jennifer; Yu, Evan Y; Kelly, Kathleen; Lin, Daniel; Dicker, Adam; Arnold, Julia; Hecht, Toby; Wicha, Max; Sears, Rosalie; Rowley, David; White, Richard; Gulley, James L; Lee, John; Diaz Meco, Maria; Small, Eric J; Shen, Michael; ... (2019). The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical cancer research, 25(23), pp. 6916-6924. American Association for Cancer Research 10.1158/1078-0432.CCR-19-1423

[img] Text
6916.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (396kB) | Request a copy

Lineage plasticity has emerged as an important mechanism of treatment resistance in prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss of luminal prostate markers, and in many cases induction of developmental programs, stem cell-like phenotypes, and neuroendocrine/neuronal features. Clinically, lineage plasticity may manifest as low PSA progression, resistance to androgen receptor (AR) pathway inhibitors, and sometimes small cell/neuroendocrine pathologic features observed on metastatic biopsy. This mechanism is not restricted to prostate cancer as other malignancies also demonstrate lineage plasticity during resistance to targeted therapies. At present, there is no established therapeutic approach for patients with advanced prostate cancer developing lineage plasticity or small cell neuroendocrine prostate cancer (NEPC) due to knowledge gaps in the underlying biology. Few clinical trials address questions in this space, and the outlook for patients remains poor. To move forward, urgently needed are: (i) a fundamental understanding of how lineage plasticity occurs and how it can best be defined; (ii) the temporal contribution and cooperation of emerging drivers; (iii) preclinical models that recapitulate biology of the disease and the recognized phenotypes; (iv) identification of therapeutic targets; and (v) novel trial designs dedicated to the entity as it is defined. This Perspective represents a consensus arising from the NCI Workshop on Lineage Plasticity and Androgen Receptor-Independent Prostate Cancer. We focus on the critical questions underlying lineage plasticity and AR-independent prostate cancer, outline knowledge and resource gaps, and identify strategies to facilitate future collaborative clinical translational and basic studies in this space.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)

UniBE Contributor:

Rubin, Mark Andrew

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Marla Rittiner

Date Deposited:

30 Jan 2020 10:55

Last Modified:

30 Jan 2020 10:55

Publisher DOI:

10.1158/1078-0432.CCR-19-1423

PubMed ID:

31363002

BORIS DOI:

10.7892/boris.138250

URI:

https://boris.unibe.ch/id/eprint/138250

Actions (login required)

Edit item Edit item
Provide Feedback